AHA announces late-breaking science lineup to be presented at 2022 Scientific Sessions
The American Heart Association Scientific Sessions will be held live in Chicago and can be attended virtually Nov. 5 to 7, and will feature nine late-breaking science sessions over 3 days.
The AHA announced the following late-breaking science lineup for the annual meeting.
Late-Breaking Science 1: The Main Event: Changing Clinical Practice —
- effectiveness of torsemide compared with furosemide in HF: the TRANSFORM-HF trial;
- chlorthalidone compared with hydrochlorothiazide for prevention of CV events in patients with hypertension: the DCP trial; and
- pemafibrate (Kowa) for the reduction of triglycerides for the prevention of CVD: the PROMINENT trial.
Late-Breaking Science 2: Breakthrough Strategies in the HF Journey —
- the first-in-human in vivo Crispr/Cas9 editing of the Ttr gene by Ntla-2001 in patients with transthyretin amyloidosis with cardiomyopathy;
- the trial of a patient-risk based health system intervention for acute HF: the COACH trial;
- early findings of the patient-reported outcome measurement in HF clinic: the PRO-HF trial; and
- a randomized trial of IV ferric derisomaltose in HF with reduced ejection fraction: the IRONMAN trial.
Late-Breaking Science 3: High Impact Trials in Intervention and Surgery —
- the 15-year outcomes of radial artery compared with right internal thoracic artery or with saphenous vein grafting: the RAPCO trial;
- steroids for the reduction of systemic inflammation after infant heart surgery: the Stress trial;
- effect of tongxinluo in patients with acute MI: the CTS-AMI trial; and
- extracorporeal membrane oxygenation for cardiogenic shock: the ECMO-CS trial.
Late-Breaking Science 4: Mindful Disruption of Chronic Hypertension Management —
- effectiveness of a village doctor-led implementation strategy for CVD in patients with hypertension: the CRHCP trial;
- BP and patient-reported outcomes in a trial to reduce inequities in care of hypertension: the Rich Life Project;
- adapted mindfulness training in participants with high in-office BP: the MB-BP Study; and
- efficacy and safety of a quadruple ultra-low-dose treatment for hypertension: the QUARTET USA trial.
Late-Breaking Science 5: Changing How we Prevent Cardiovascular and Renal Disease —
- efficacy of secondary prevention with combination statin and eicosapentaenoic acid: the RESPECT-EPA trial;
- lipoprotein(a) reduction with small interfering RNA: the OCEAN(a)-DOSE trial;
- empagliflozin and CV outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial; and
- low-dose statin compared with placebo and six dietary supplements on lipid and inflammatory biomarkers: the SPORT trial.
Late-Breaking Science 6: Drugs and Strategies in ACS and Revascularization —
- bivalirudin with post-PCI high-dose infusion compared with heparin monotherapy during primary PCI in STEMI: the BRIGHT-4 trial;
- the efficacy and safety of indobufen compared with aspirin after coronary drug-eluting stent implantation: the OPTION trial;
- a precision care strategy compared with usual testing to guide management of stable patients with suspected CAD: the PRECISE trial; and
- an interim follow-up report from ISCHEMIA-EXTENDed.
Late-Breaking Science 7: Preventing Limb Loss Through Vascular Interventions and Venous Therapies —
- best endovascular compared with best surgical therapy for patients with chronic limb threatening ischemia: the BEST-CLI trial;
- a quality of life analysis of patients in the BEST-CLI trial;
- rivaroxaban (Xarelto, Janssen/Bayer) to reduce risk for major venous and arterial thrombotic events, hospitalization and death in outpatients with COVID-19: the PREVENT-HD trial; and
- A multicenter trial of a universal electronic health record-based venous thromboembolism risk assessment model integrated for clinical decision support for prevention of thromboembolism in hospitalized patients: the IMPROVE trial.
Late-Breaking Science 8: Treating Atrial and Supraventricular Arrhythmias —
- “first-line” rhythm therapy for atrial fibrillation progression: the PROGRESSIVE-AF trial;
- self-administered etripamil (Milestone Pharmaceuticals) for termination of spontaneous paroxysmal supraventricular tachycardia: the RAPID trial;
- efficacy and safety of botulinum toxin type A for the prevention of postoperative AF in patients who underwent cardiac surgery: the phase 2 NOVA trial; and
- a trial to evaluate a shared decision-making pathway for AF stroke prevention: the ENHANCE-AF trial.
Late-Breaking Science 9: Resistant Hypertension: A Pressure Cooker —
- top-line results of the first-in-class aminopeptidase A inhibitor firibastat (Quantum Genomics) for resistant hypertension: the FRESH trial;
- sustained BP lowering with a dual endothelin receptor antagonist, aprocitentan (Idorsia), for resistant hypertension: the PRECISION trial;
- results from the phase 2 trial evaluating the efficacy and safety of baxdrostat (CinCor) in patients with resistant hypertension: the BrigHTN trial; and
- 6-month effects of radiofrequency renal denervation on BP in patients already taking antihypertensives: SPYRAL HTN-ON Med.
Healio | Cardiology Today will be on-site in Chicago to report the latest news from the AHA Scientific Sessions, with physician perspective, researcher interviews and more. Follow our breaking updates here and by following @CardiologyToday on Twitter.